Victoria Merino
Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain
Agustín Garrido
Department of Pneumology, Thorax Institute, Hospital Clinic of Barcelona, SpainICREA, Barcelona, Spain


Alzheimer's disease (AD), which is characterized by gradual cognitive deterioration, is a serious worldwide health issue. Early AD identification is essential for prompt treatment and better patient outcomes. Digital biomarkers, which are products of many digital technologies, present a potential way to detect cognitive deterioration in AD early on. This article examines a variety of digital biomarkers and how they can be used to detect Alzheimer's disease, including cognitive assessment apps, eye tracking technology, voice analysis, keyboard interaction, wearables, neuroimaging, sensor-equipped homes, machine learning, biometric data, virtual reality, and social media analysis. Digital biomarkers have a lot of potential, but they also come with difficulties including validation, data protection, ethics, and regulatory issues. However, adopting these cutting-edge techniques offers the potential of earlier diagnosis, individualized therapy, and a better comprehension of Alzheimer's disease, marking a critical step towards improved AD management and, in the end, a cure.

Keywords:Alzheimer Disease (AD), SPSS software, Digital Biomarkers (DB)